Image de couverture de livre

Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Marc Codaccioni, Rosalind L. Southall, Jean Dinh, Trevor N. Johnson
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	The Journal of Clinical Pharmacology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization
par: Seung‐Hyun Jeong, et autres
Publié: (2026)

Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations
par: Nashid Farhan, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
par: Mary P. Choules, et autres
Publié: (2025)

Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
par: Hongxia Jia, et autres
Publié: (2025)

Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
par: Lucy Lee, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates
par: Ailing Cao, et autres
Publié: (2024)

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
par: Cornelius Cilliers, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment
par: Wanhong Wu, et autres
Publié: (2025)

Precision Pharmacokinetics of Quetiapine: A Physiologically Based Model Incorporating Liver Cirrhosis and CYP3A4 Polymorphisms
par: Seung‐Min Lee, et autres
Publié: (2025)

Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine‐to‐Caffeine Metabolic Ratio: A Pharmacokinetic Study
par: Christina Gade, et autres
Publié: (2026)

Physiologically Based Pharmacokinetic Modeling to Predict Nicotine Pharmacokinetics of Nicotine Pouches Under Naturalistic Use Conditions
par: Ali Salehi, et autres
Publié: (2025)

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
par: Peile Wang, et autres
Publié: (2024)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
par: Yi‐An Bi, et autres
Publié: (2024)

Mechanistic Framework to Predict Maternal‐Placental‐Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach
par: Marya Antônya Werdan Romão, et autres
Publié: (2024)

Simultaneously Predicting Pharmacokinetics of Loratadine and Desloratadine in Children Using a Whole‐Body Physiologically Based Pharmacokinetic Model
par: Tianlei Liu, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetic Changes of Topiramate During Pregnancy and Recommend Dose Adjustments
par: Yuying Chen, et autres
Publié: (2025)

Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants
par: Shichang Miao, et autres
Publié: (2024)

Physiologically Based Pharmacokinetic Modeling to Evaluate Drug‐Drug Interactions of Tacrolimus With Ritonavir, a CYP3A Irreversible Inhibitor: Applications for Dosing Optimization in Transplant Patients
par: Yanjun Jiang, et autres
Publié: (2025)

Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Secukinumab: Dose Exploration in Pediatric Patients with Plaque Psoriasis
par: Liu Zhiwei, et autres
Publié: (2025)

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib
par: Martha Gonzalez, et autres
Publié: (2025)

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
par: Yoo Jin Jang, et autres
Publié: (2024)

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
par: Sejung Hwang, et autres
Publié: (2024)

Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling
par: Shixing Zhu, et autres
Publié: (2024)

In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers
par: Megumi Iwai, et autres
Publié: (2024)

Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically‐Based Pharmacokinetic Model
par: Yuran Cao, et autres
Publié: (2025)

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
par: Megumi Iwai, et autres
Publié: (2025)

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
par: Xiaoyu Men, et autres
Publié: (2024)

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
par: Yan‐ou Yang, et autres
Publié: (2025)

Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
par: Annie Lumen, et autres
Publié: (2024)

Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
par: Joseph Burnett, et autres
Publié: (2025)

Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population
par: Victoria Etges Helfer, et autres
Publié: (2026)

Effect of Itraconazole, a CYP3A4 Inhibitor, and Rifampin, a CYP3A4 Inducer, on the Pharmacokinetics of Vatiquinone
par: Lucy Lee, et autres
Publié: (2024)

Statin Drug‐Drug Interactions: Pharmacokinetic Basis of FDA Labeling Recommendations and Comparison Across Common Tertiary Clinical Resources
par: James Mease, et autres
Publié: (2024)

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease
par: Islam R. Younis, et autres
Publié: (2025)

Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in Pregnancy
par: Xiaomei I. Liu, et autres
Publié: (2025)

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
par: Emily Mannix, et autres
Publié: (2026)

Comparison of Population Pharmacokinetics‐Related Information in Drug Labeling Between Japan, the United States, and the European Union
par: Kei Fukuhara, et autres
Publié: (2025)

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects
par: Martha Gonzalez, et autres
Publié: (2025)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure
par: Luke Fostvedt, et autres
Publié: (2024)

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
par: Aiden‐Hung P. Nguyen, et autres
Publié: (2026)